OVAS News 7.78 Ovascience Inc (OVAS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ovascience Inc (OVAS) 7.78 $OVAS

How OvaScience (OVAS) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:42AM CDT
OvaScience has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front

OvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
Business Wire - Tue Mar 18, 7:31AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 518,630 shares of common stock at the public offering price of $10.00 per share. As a result, total gross proceeds to OvaScience from this offering are $55.2 million before deducting the underwriting discounts, commissions and estimated expenses.

OvaScience to Present at the 26th Annual ROTH Conference
Business Wire - Thu Mar 06, 7:31AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience will present at the 26th Annual ROTH Conference on Tuesday, March 11 at 12:30pm Pacific Standard Time. The conference will take place at the Ritz-Carlton in Laguna Niguel, California.

OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:48AM CST
OvaScience fell 9.5% last trading session, reversing the recent trend

Nasdaq stocks posting largest volume increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

OvaScience Prices $50 Million Public Offering of Common Stock
Business Wire - Tue Mar 04, 7:35AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced the pricing of $10.00 per share for its previously announced underwritten public offering of 5,000,000 shares of its common stock. Gross proceeds to OvaScience from this offering are expected to be approximately $50 million, and the Company intends to use the net proceeds to fund OvaPrime(SM) preclinical studies and the anticipated 2015 international launch, establish an international subsidiary, expand the AUGMENT(SM) international launch, and for other general corporate purposes.

OvaScience Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:05PM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience.

OvaScience Reports Fourth Quarter and Year End 2013 Financial Results
Business Wire - Thu Feb 27, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported fourth quarter and year end 2013 financial results, and highlighted recent accomplishments.

OvaScience (OVAS) in Focus: Stock Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose nearly 6% on the day.

2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.

OvaScience Issued Two U.S. Patents Covering AUGMENT(SM) Fertility Treatment
Business Wire - Wed Feb 12, 7:30AM CST
OvaScience(SM) (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced the issuance of two United States patents covering its AUGMENT(SM) fertility treatment. AUGMENT is based on the Company's egg precursor cell (EggPC(SM)) technology and is being developed to improve egg quality and the success of in vitro fertilization (IVF). AUGMENT will be available in international IVF clinics this year.

OvaScience Appoints Fertility Pioneer Jamie Grifo M.D., Ph.D., to Clinical Advisory Board
Business Wire - Tue Feb 04, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo, M.D., Ph.D., of the New York University (NYU) Fertility Center and the Division of Reproductive Endocrinology at the NYU School of Medicine, to its Clinical Advisory Board.

OvaScience to Present at Upcoming Conferences
Business Wire - Mon Feb 03, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that the Company's management team will present at two upcoming conferences in February. The conference and OvaScience presentation details are as follows:

OvaScience (OVAS) in Focus: Stock Tumbles 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:34AM CST
OvaScience stock tumbles 8% yesterday, continuing the recent downtrend

OvaScience Provides Update on Pipeline Advancements and Commercial Plans; New Potential Fertility Treatment OvaPrime(SM) to Launch in 2015
Business Wire - Mon Jan 13, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPC(SM)) technology platform. OvaScience expects to commercialize AUGMENT(SM) in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrime(SM), in 2015.

OvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company's Board of Directors
Business Wire - Fri Jan 10, 7:29AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Marc Kozin, former President of L.E.K. Consulting's North American practice, to the Company's Board of Directors.

OvaScience announces management changes
M2 - Fri Jan 10, 3:41AM CST
OvaScience (Nasdaq:OVAS), a life sciences company focused on treatments for infertility, announced on Thursday that it has appointed David Stern to the position of executive vice president, Global Commercial Operations, effective February 2014.

OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
Business Wire - Thu Jan 09, 7:29AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of David Stern to the position of Executive Vice President, Global Commercial Operations, in preparation for the Company's international introduction of AUGMENT(SM). Mr. Stern joins OvaScience from EMD Serono, Inc. (an affiliate of Merck KGaA), where he most recently served as Head Global Business Franchise, Fertility. He will assume his new role in February 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 59

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 80

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 89

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 77

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 104

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 16

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 31

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 29

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading

Top 5 Most Recently Viewed Articles

Join SeaStar Medical's CEO for Exciting Insights on Benzinga

Updated Category News Views 157

Join the CEO of SeaStar Medical on Benzinga All Access SeaStar Medical Holding Corporation (Nasdaq: ICU), recognized for its innovative approach in the healthcare sector, is proud to announce an exciting event featuring its CEO, Eric Schlorff. The event, scheduled for today, promises to be a significant moment for those interested in advancements in treatments for...

Continue Reading
E-Commerce Fuels Surge in Europe's Logistics Market Growth

Updated Category News Views 220

Surge in Europe's Logistics Market Driven by E-Commerce The logistics market in Europe is poised for remarkable growth, projected to expand by approximately USD 48.4 billion between 2025 and 2029. This growth trajectory, which reflects a compound annual growth rate (CAGR) of 3.4%, is predominantly fueled by the booming e-commerce sector. As consumer behaviors shift to...

Continue Reading
Procept Bio's 18% Dive: Unpacking Fraud Allegations

Updated Category News Views 64

Procept's Plunge: Not Your Average Market Tumble When a stock takes an 18% nosedive, it’s like ringing alarm bells down Wall Street. That’s exactly what happened with Procept BioRobotics Corporation (NASDAQ:PRCT), when it found itself knee-deep in controversies over alleged shady financial practices. The Allegations: Inflated Sales and Bulk Orders Procept allegedly...

Continue Reading
Key Outcomes from AB Akola Group's Latest Shareholder Meeting

Updated Category News Views 219

AB Akola Group's Extraordinary General Meeting Insights The Extraordinary General Meeting of AB Akola Group brought together shareholders to discuss various important agendas concerning the company's future. With a total shareholding of 167,170,481 shares, of which 166,566,819 held voting rights, the company witnessed an engaging assembly of its stakeholders. Major...

Continue Reading
GO Residential REIT Secures New Financing for Growth and Flexibility

Updated Category News Views 230

Enhancing Financial Stability: GO Residential REIT's New Financing GO Residential Real Estate Investment Trust (REIT) is thrilled to announce the successful refinancing of its prestigious property, One East River Place. This strategic move is designed to unlock significant liquidity and enhance the REIT's financial flexibility. The refinancing involves a new five-year...

Continue Reading